Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.
Donald R. Joseph named chief legal officer at KaloBios
KaloBios Pharmaceuticals ($KBIO) appointed Donald R. Joseph to be the company's chief legal officer. Joseph was most recently CEO of BIO Ventures for Global Health, and the COO there before that. He also served as COO at the Institute for OneWorld Health, a nonprofit drug-development company. "Don has a long and successful track record as a general counsel and senior executive and his knowledge and experience will serve KaloBios well," said KaloBios President and CEO David Pritchard. "Moreover, his primary therapeutic areas of experience, which include oncology, infectious diseases, and antibody technology, are directly relevant to KaloBios' own pipeline of patient-targeted, first-in-class monoclonal antibodies. I am very pleased to welcome Don to the KaloBios management team." Release
|
Pharma
> Bristol-Myers Squibb's ($BMY) board of directors has elected Dinesh Paliwal to the board. Paliwal is currently the chairman, president and CEO of Harman International Industries. Release
> Tris Pharma has named Janet Penner as president of its new generic pharmaceuticals business. Most recently, Penner headed sales and marketing at CorePharma. Release
Biotech
> Albany Molecular Research ($AMRI) bumped Susan Collins up to the role of director of business development. She was previously region sales director at the company. Release
> QPharma appointed Maria A. Galdos as the company's senior manager of healthcare compliance. Release
> Allen Shofe, executive vice president of corporate affairs at Emergent BioSolutions ($EBS), joined the board of directors at MdBio Foundation. Release
> Promedior appointed entrepreneur Howard J. Weisman to the company's board of directors. Weisman is currently president and CEO at Seventh Sense BioSystems. Release
> Southern Research Institute's board of directors has selected Arthur Tipton to serve as president and CEO. Tipton replaces John Secrist, III, who served as president and CEO of Southern Research Institute for 7 years and is retiring. Release
> EPIRUS Biopharmaceuticals has appointed Thomas Shea as chief financial officer. Most recently, Shea served as CFO and treasurer of Euthymics Bioscience, Neurovance, and EBI Life Sciences. Release
> Dr. Wulf Fischer-Knuppertz took over as CEO of BIOCRATES Life Sciences AG. Most recently, Fischer-Knuppertz was general manager with Fisher Scientific and before that had held leading positions at Roche Diagnostics. Release
> CytoDyn has appointed Anthony D. Caracciolo as chairman of the company's board of directors. Caracciolo has been a director at CytoDyn since December 2011 and was formerly employed at Gilead Sciences ($GILD), where he served as senior vice president of manufacturing and operations, and was a senior member of Gilead's executive committee. Release
> Andri Sveinsson and Kristjan Johannesson have been appointed to Iceland-based Kerecis's board of directors. Release
CRO
> PSI CRO named Andrea Cracraft director of clinical operations in North America. Cracraft has more than 15 years of experience in clinical research. Release